Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Milestone Scientific (MLSS) Shares Outstanding (Diluted Average) (2016 - 2025)

Milestone Scientific (MLSS) has disclosed Shares Outstanding (Diluted Average) for 16 consecutive years, with $82.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 2.85% to $82.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.1 million through Dec 2025, up 2.85% year-over-year, with the annual reading at $82.1 million for FY2025, 2.85% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $82.1 million in Q4 2025 for Milestone Scientific, roughly flat from $82.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $82.3 million in Q3 2025 to a low of $66.6 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $73.9 million across 5 years, with a median of $70.6 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 33.88% in 2021 and later grew 1.97% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $68.8 million in 2021, then grew by 2.4% to $70.5 million in 2022, then rose by 2.63% to $72.3 million in 2023, then rose by 10.31% to $79.8 million in 2024, then grew by 2.85% to $82.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MLSS at $82.1 million in Q4 2025, $82.3 million in Q3 2025, and $79.8 million in Q4 2024.